NO940597L - Isolering, vekst, differensiering og genslöyd på menneskers muskelceller - Google Patents

Isolering, vekst, differensiering og genslöyd på menneskers muskelceller

Info

Publication number
NO940597L
NO940597L NO940597A NO940597A NO940597L NO 940597 L NO940597 L NO 940597L NO 940597 A NO940597 A NO 940597A NO 940597 A NO940597 A NO 940597A NO 940597 L NO940597 L NO 940597L
Authority
NO
Norway
Prior art keywords
differentiation
isolation
growth
muscle cells
gene silencing
Prior art date
Application number
NO940597A
Other languages
English (en)
Other versions
NO940597D0 (no
Inventor
Helen M Blau
Simon M Hughes
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of NO940597D0 publication Critical patent/NO940597D0/no
Publication of NO940597L publication Critical patent/NO940597L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det fremstilles myoblaster, hensiktsmessig i lavt eller serum-fritt medium, for anvendelse til innføring i en pattedyrvert, særlig en menneskevert, for behandling av sykdommer i muskelvev eller for å virke som bærere for genetiske evner, særlig for korrigering av en genetisk defekt eller for fremstilling av et løselig protein som kan anvendes i terapi for pattedyrverten. Myoblaster som innføres i vev, er i stand til å migrere til steder langt fra injeksjonsstedet, hvilket utvider deres virkningsområde.
NO940597A 1991-08-22 1994-02-21 Isolering, vekst, differensiering og genslöyd på menneskers muskelceller NO940597L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/748,348 US5538722A (en) 1989-06-13 1991-08-22 Isolation, growth, differentiation and genetic engineering of human muscle cells
PCT/US1992/006983 WO1993003768A1 (en) 1991-08-22 1992-08-19 Isolation, growth, differentiation and genetic engineering of human muscle cells

Publications (2)

Publication Number Publication Date
NO940597D0 NO940597D0 (no) 1994-02-21
NO940597L true NO940597L (no) 1994-04-19

Family

ID=25009080

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940597A NO940597L (no) 1991-08-22 1994-02-21 Isolering, vekst, differensiering og genslöyd på menneskers muskelceller

Country Status (8)

Country Link
US (1) US5538722A (no)
EP (1) EP0667791A4 (no)
JP (1) JPH07501688A (no)
KR (1) KR100275304B1 (no)
AU (1) AU659673B2 (no)
CA (1) CA2116118A1 (no)
NO (1) NO940597L (no)
WO (1) WO1993003768A1 (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
EP0584339A4 (en) * 1992-03-04 1996-02-28 Jon A Wolff Method of delivering therapeutic substances to the brain
US6432711B1 (en) * 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
CA2183551A1 (en) * 1993-11-10 1995-05-18 Babru B. Samal Gene therapy vector for the treatment of low or defective red blood cell production
US5935849A (en) 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5833979A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
GB9419048D0 (en) * 1994-09-20 1994-11-09 Watt Diana J Treatment of muscular disorders
US6495364B2 (en) * 1995-05-23 2002-12-17 Neurotech, S.A. Mx-1 conditionally immortalized cells
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
ES2167939T3 (es) 1997-08-13 2002-05-16 Biontex Lab Gmbh Nuevas poliaminas, su preparacion y usos.
US6866842B1 (en) * 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
WO1999056785A2 (en) 1998-05-01 1999-11-11 University Of Pittsburgh Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
EP1048724A1 (en) * 1999-04-27 2000-11-02 Transgene S.A. Human myoblast cell lines and their uses
EP1048725B1 (en) * 1999-04-27 2005-07-06 Transgene S.A. Process for production of mammalian cell lines
WO2001000031A1 (en) * 1999-06-25 2001-01-04 Baylor College Of Medicine Stem cells derived from skeletal muscle
WO2001007568A2 (en) 1999-07-23 2001-02-01 Diacrin, Inc. Muscle cells and their use in cardiac repair
US20030113301A1 (en) * 1999-07-23 2003-06-19 Albert Edge Muscle cells and their use in cardiac repair
ATE365045T1 (de) 2000-04-14 2007-07-15 Univ Pittsburgh Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
DE10026480A1 (de) * 2000-05-29 2001-12-13 Augustinus Bader Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
WO2002066076A1 (en) * 2001-02-21 2002-08-29 Melbourne Neuromuscular Research Institute A method of treatment and agents useful for same
WO2002067867A2 (en) * 2001-02-23 2002-09-06 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
AU2003220562A1 (en) * 2002-04-01 2003-10-20 Peter K. Law Cellular transplantation for heart regeneration
US20040009155A1 (en) * 2002-07-12 2004-01-15 Maria Palasis Method for sustaining direct cell delivery
EP1539282A2 (en) * 2002-08-06 2005-06-15 GenVec, Inc. Improved injection system
CN103230415B (zh) * 2003-04-25 2016-05-04 匹兹堡大学联邦制高等教育 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc）
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US20060263338A1 (en) * 2005-03-04 2006-11-23 Jacoby Douglas B Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts
JP2008537942A (ja) * 2005-03-31 2008-10-02 マイトジェン， インコーポレイテッド 心疾患のための処置
AU2006244197A1 (en) * 2005-05-09 2006-11-16 Mytogen, Inc. Cellular cardiomyoplasty as supportive therapy in patients with heart disease
EP2097088B2 (en) * 2006-11-28 2024-06-12 University of Pittsburgh - of the Commonwealth System of Higher Education Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US9121009B2 (en) * 2006-12-18 2015-09-01 University of Pittsburgh—Of the Commonweath System of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
US20100158875A1 (en) 2006-12-18 2010-06-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
AU2008205278B2 (en) 2007-01-11 2014-06-12 University Of Pittsburgh Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
US20080208164A1 (en) * 2007-02-28 2008-08-28 Innovacell Biotechnologie Gmbh Methods for the treatment of anal incontinence
ATE554160T1 (de) * 2007-05-29 2012-05-15 Univ Pittsburgh Knochenaufbau anhand von vorläuferzusammensetzungen aus muskeln und behandlungen damit
BRPI0813352A2 (pt) * 2007-06-15 2014-12-30 Ethicon Inc Composições de fragmento de tecido para o tratamento de incontinência
EP2209482A4 (en) 2007-10-04 2016-06-01 Univ Pittsburgh SKELETAL MUSCLE REINFORCEMENT WITH MUSCLE PRESERVATORY COMPOSITIONS AND TREATMENTS THEREOF
US9199003B2 (en) * 2008-08-18 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US20100233138A1 (en) * 2008-11-07 2010-09-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof
FR2960783B1 (fr) 2010-06-04 2012-07-27 Ass Pour Les Transferts De Technologies Du Mans Membrane fonctionnalisee pour chambre d'encapsulation de cellules produisant au moins une substance d'interet therapeutique et organe bioartificiel comprenant une telle membrane
US9295696B2 (en) 2012-06-08 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for restoring or rejuvenating stem/progenitor cell function
JP2015531230A (ja) 2012-09-24 2015-11-02 イノヴァセル ビオテヒノロギー アーゲー 骨格筋由来細胞についての効力アッセイ
EP3095509A1 (en) 2015-05-18 2016-11-23 Defymed Membranes functionalized with heparin for bioartificial organs
ES2962633T3 (es) 2015-06-11 2024-03-20 Univ Illinois Células quiméricas para tratar la distrofia muscular y método para tratar distrofias musculares
AU2018375315A1 (en) 2017-11-28 2020-06-04 The Board Of Trustees Of The University Of Illinois Multi-chimeric cell and therapy for transplantation and treatment of immune deficiencies and genetic disorders
RS64241B1 (sr) 2017-12-14 2023-06-30 Innovacell Ag Postupci za dobijanje ćelija izvedenih iz mišića
US20220257793A1 (en) * 2019-05-29 2022-08-18 Institute Of Zoology, Chinese Academy Of Sciences Compositions and use of engineered myogenic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443546A (en) * 1980-07-07 1984-04-17 The Beth Israel Hospital Association Process and composition for propagating mammalian cells
US4520821A (en) * 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
DE69034078T2 (de) * 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
JP3244696B2 (ja) * 1989-06-13 2002-01-07 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー ヒト筋肉細胞の単離、増殖および分化
EP0437576B1 (en) * 1989-07-25 2002-07-03 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991012329A2 (en) * 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
CA2128616A1 (en) * 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
EP0651824A4 (en) * 1992-04-10 1997-02-26 Fox Chase Cancer Center TRANSCRIPTION ELEMENT FOR CONTROLLING THE INCREASED GENE EXPRESSION IN MYOBLASTEN.
AU4385393A (en) * 1992-05-29 1993-12-30 General Hospital Corporation, The Arterial introduction of myoblasts

Also Published As

Publication number Publication date
US5538722A (en) 1996-07-23
AU659673B2 (en) 1995-05-25
JPH07501688A (ja) 1995-02-23
EP0667791A1 (en) 1995-08-23
CA2116118A1 (en) 1993-03-04
AU2515792A (en) 1993-03-16
NO940597D0 (no) 1994-02-21
WO1993003768A1 (en) 1993-03-04
KR100275304B1 (ko) 2000-12-15
EP0667791A4 (en) 1996-05-08

Similar Documents

Publication Publication Date Title
NO940597L (no) Isolering, vekst, differensiering og genslöyd på menneskers muskelceller
Silverman et al. Angiogenic activity of adipose tissue
Eccles et al. Immunologically-mediated restraint of latent tumour metastases
US4604234A (en) Protein having cell growth stimulating action, composition thereof and method for producing the same
Morykwas et al. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation
Ronfard et al. Use of human keratinocytes cultured on fibrin glue in the treatment of burn wounds
DE69435096T2 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
CN101856517B (zh) 基于组织工程材料的黑素细胞的培养方法及其应用
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
NO890587L (no) Nye proteiner med faktor viii aktivitet: fremgangsmaate for fremstilling derav ved anvendelse av genetisk omkonstruerte celler og farmasoeytiske sammensetninger som inneholderdisse.
NO934163L (no) HER4 human reseptor-tyrosinkinase
US4197291A (en) Hydrolytic enzyme material
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
CN108619086A (zh) 一种治疗组织损伤的细胞凝胶制剂及其用途和所用的保持冻存细胞活性的凝胶溶液
NO924323L (no) Nye hybridtransformerende vekstfaktorer
CA2368677A1 (en) Intramyocardial injection of autologous bone marrow
RU98107327A (ru) Нейротрансплантация с использованием плюрипотентных нейроэпителиальных клеток
JPH03503167A (ja) 部位指定血管形成素子とその使用法
BR0312365A (pt) Meio de cultura autólogo de células-mães progenitoras autólogas humanas, métodos para a preparação do mesmo e de uma composição de células-mães progenitoras autólogas humanas e para a obtenção de células-mães progenitoras musculares autólogas humanas, emprego de um meio de cultura autólogo de células-mães progenitoras autólogas humanas, procedimento para a obtenção de células-mães progenitoras musculares autólogas humanas e procedimento terapêutico de cardiomioplastia celular autóloga, composição enriquecida com células-mães progenitoras musculares autólogas humanas e composição farmacêutica
AU754874B2 (en) A method for inducing production of growth factors
CN104152401A (zh) 一种适于中国人表皮黑素细胞体外培养的chmm1培养基
Lozano et al. Use of tissue expanders with external ports
Sakai et al. Stimulation of hepatocytes and lymphocytes in vitro by liver regeneration
ATE267843T1 (de) Verfahren zur herstellung von selbstvernetzten hyaluronsäuren und deren derivaten mittels superkritischer anti-lösungsmittel
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application